Three months of romosozumab did not improve hip bone strength, but 12 months did, supporting completion of the full regimen in patients with osteoporosis.
|Slideshows|January 23, 2019
CV Risk in Rheumatic Disease
Author(s)Mark L. Fuerst
(1) Inflammatory diseases raise risk of venous thromboembolism; (2) antiphospholipid antibodies play a role in MI; (3) persistent hyperuricemia predicts mortality.
Advertisement
Advertisement
Related to this article
On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Advertisement
Advertisement